FDA Approves Axsome Therapeutics Alzheimer Agitation Drug
The U.S. FDA approved an Axsome Therapeutics drug to treat agitation in Alzheimer patients. The company announced the regulatory decision this Friday.
Xurve View
Insights:
Xurve View
AXSOME THERAPEUTICS INC secured United States FDA approval for its drug to treat Alzheimer's-related agitation on April 30. This decision opens a market serving a high-unmet-need population, positioning the developer to capture revenue from a condition affecting millions.
